Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trialResearch article Published on 2022-06-032022-10-05 Journal: EClinicalMedicine [Category] 신약개발, 임상, 치료제, [키워드] 95% CI Admission Adverse AMED assigned calculated camostat Characteristics Ciclesonide clinical Clinical finding Clinical management Combination combination therapy comparable COVID-19 COVID-19 infection deaths decrease development discharge Effectiveness enrolled evaluated event Favipiravir finding funding group groups healthcare worker hospital discharge rate Hospital stay Hospitalization Hospitalized Japan Japanese lack less limitation median time Ministry of Health monotherapy no significant difference number Open-label oxygen participant Patient patients patients with moderate Phase 3 phase 3 study Pneumonia positive Primary outcome randomized clinical trial Randomized controlled trial Randomly Registered registry Research SARS-CoV-2 Severe COVID-19 Infection significantly higher significantly lower single-center statistically supported therapy Treatment vaccination Version Welfare [DOI] 10.1016/j.eclinm.2022.101484 [Article Type] Research article
Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs프로테아제 억제제 Camostat Mesyalte는 인간이 조작한 소형 폐에서 야생형 SARS-CoV-2 및 D614G 바이러스 진입을 차단합니다Article Published on 2022-06-012022-09-11 Journal: Biomaterials [Category] Coronavirus, COVID19(2023년), SARS, 치료제, [키워드] 3D model alveolar alveolar epithelial cell AT2 block camostat catastrophic cell line cell lines COVID-19 Culture D614G develop distal Effect epithelial epithelial cells evaluate Ex vivo highlight human lung in vitro model induce Infection inhibitor involved lentivirus lung lung epithelium maturation moderate organ organ culture organoids pandemic Pathogenesis pathogenesis of COVID-19 phenotype platform pluripotent stem cell Prevent progression Protease inhibitor provided pseudotyped real time reduced Research respiratory tract SARS-CoV-2 SARS-CoV-2 pandemic significantly the SARS-CoV-2 tissue treat type 2 alveolar epithelial cells viral entry viral infection viral infections virulent while wild type wildtype [DOI] 10.1016/j.biomaterials.2022.121509 PMC 바로가기 [Article Type] Article
Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19Research article Published on 2022-03-012022-10-05 Journal: Saudi Pharmaceutical Journal : SPJ [Category] 치료법, [키워드] acute respiratory syndrome binding affinity camostat catalytic site Compound Consequences coronavirus coronavirus disease COVID-19 effective Efficacy exhibited fatality indicate Infection inhibitor inhibitors main protease MM/PBSA molecular molecular docking Occurrence pandemic Potential treatment Prevent protease TMPRSS2 proteolytic activation SARS-CoV-2 screened serine protease severe acute respiratory syndrome coronavirus 2 these compound TMPRSS2 TMPRSS2 inhibitor transmembrane Treatment variant [DOI] 10.1016/j.jsps.2022.01.005 [Article Type] Research article
Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening고처리량 스크리닝 적용을 위한 안정적인 SARS-CoV-2 레플리콘 시스템 구축Article Published on 2022-03-012022-09-11 Journal: Antiviral Research [Category] SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Antiviral Antiviral effect antiviral effects Bacterial bacterial artificial chromosome biosafety level Biosafety Level 3 BSL2 BSL3 camostat Cell cell line cell lines cells chromosome compounds condition conditions coronavirus COVID-19 examined exhibited Favipiravir gene encoding In vitro infection inhibited interferon level 3 luciferase luciferase activity molnupiravir Neomycin Novel coronavirus Particles powerful tool produced RdRP RdRp inhibitor Remdesivir Renilla Renilla luciferase replicon reported RNA SARS-coronavirus SARS-coronavirus-2 SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 sgRNA sgRNAs stable cell stable cell line suppressed the SARS-CoV-2 transient transfection transiently transfected Treatment VeroE6 cells Viral proteins viral replication [DOI] 10.1016/j.antiviral.2022.105268 PMC 바로가기 [Article Type] Article
In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 ActivityBrief Report Published on 2022-02-142022-10-28 Journal: Viruses [Category] COVID-19, COVID19(2023년), SARS, [키워드] activity acute respiratory syndrome Analysis anti-SARS-CoV-2 Anti-SARS-CoV-2 Activity anti-SARS-CoV-2 agent Antiviral effect binding binding affinity camostat contribute coronavirus covalent bond COVID-19 CPE Cytopathic effect derivative derivatives element expected greater inhibition interact investigated molecular nafamostat predicted reported SARS-CoV-2 shown significantly synthesis TMPRSS2 TMPRSS2 inhibitor transmembrane serine protease unique weakened [DOI] 10.3390/v14020389 PMC 바로가기 [Article Type] Brief Report
Executable network of SARS-CoV-2-host interaction predicts drug combination treatmentsArticle Published on 2022-02-142022-10-04 Journal: NPJ Digital Medicine [Category] 바이오마커, 신약개발, 치료제, [키워드] apilimod approved drugs camostat Cellular signalling networks Combination combination therapy COVID-19 pandemic COVID-19 treatment Disease progression drug combination Dynamic networks early stage effective Healthcare system human Caco-2 cells identify in silico Interaction late stage new drug combinations nine pandemic performed predict predicted Regulatory networks resource respond SARS-CoV-2-host interaction severe disease Stage target the disease Treatment viral replication Virtual drug screening [DOI] 10.1038/s41746-022-00561-5 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cellsSARS-CoV-2 Omicron 변이체는 TMPRSS2 발현 세포에서 Delta 변이체와 비교할 때 복제 및 융합 활성이 덜 효율적입니다.Comparative Study Published on 2022-01-192022-09-10 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] Affect Antiviral effect B.1.1.529 bafilomycin Calu3 CaLu3 cells camostat Cell cell line cells Characteristics Chloroquine clinical manifestation clinical manifestations competition Delta delta variant Delta variants disease severity Endocytic pathway entry pathway Immune escape Infection inhibit inhibited inhibiting less mutations not enhanced omicron Omicron variant replicated Replication robust SARS-CoV-2 Serine TMPRSS2 TMPRSS2 expression TMPRSS2 pathway transmembrane serine protease transmembrane serine protease 2 Transmissibility variant variants viral replication Virological [DOI] 10.1080/22221751.2021.2023329 PMC 바로가기 [Article Type] Comparative Study
An update of anti-viral treatment of COVID-19COVID-19의 항바이러스 치료 업데이트Review Published on 2021-12-172022-09-10 Journal: Turkish Journal of Medical Sciences [Category] SARS, 치료제, [키워드] ACE-2 Administered Anti-viral treatment Antiviral AT-527 biological processe biological processes bromhexine camostat clinical trial clinical trials convalescent plasma COVID-19 drug dutasteride early phase effective effective antiviral treatment evaluated Favipiravir fluvoxamine group Host host protein host proteins human cell Hydroxychloroquine include inhibitor inhibitors interfere interferons Ivermectin knowledge Laboratory lactoferrin Lopinavir Lopinavir/ritonavir merimepodib molnupiravir moment monoclonal antibodies monoclonal antibody nanobodies natural immunity niclosamide nitazoxanide pandemic PF-07304814 PF-07321332 Plitidepsin protease Protein Proteins proxalutamide PTC299 RCTs Remdesivir Result Ritonavir RNA SARS-CoV-2 subject Support target protein target proteins the disease to define Treatment treatment for COVID-19 treatment of COVID-19 Trial umifenovir Viral viral entry Viral RNA virus [DOI] 10.3906/sag-2106-250 PMC 바로가기 [Article Type] Review
Virtual Screening on Marine Natural Products for Discovering TMPRSS2 InhibitorsChemistry Published on 2021-10-122022-10-31 Journal: Frontiers in Chemistry [Category] COVID-19, [키워드] ACE2 ADME angiotensin-converting enzyme 2 applied blocked blockers camostat CAS Cell cellular compounds COVID-19 distribution docking exhibited homology homology model inhibit inhibitor inhibitory inhibitory activity inhibitory effect introduced metabolism MNP molecular docking Molecular modeling natural performed pharmacokinetic priming product SARS-CoV-2 SARS-CoV-2 entry Screening shown Spike protein three-dimensional structure TMPRSS2 transmembrane serine protease Virtual screening virus were used [DOI] 10.3389/fchem.2021.722633 PMC 바로가기 [Article Type] Chemistry
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells새로운 종류의 TMPRSS2 억제제는 SARS-CoV-2 및 MERS-CoV 바이러스 진입을 강력하게 차단하고 인간 상피 폐 세포를 보호합니다410 Published on 2021-10-112022-09-10 Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 신약개발, [키워드] activate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Antiviral antiviral drug block broad-spectrum antivirals Calu Calu-3 calu-3 cells camostat can be used cell entry chimeric clinical development coronavirus COVID-19 COVID-19 treatment Cytopathic effect cytopathic effects drug drug candidate drug design Drug discovery drugs Efficacy epithelial epithelial cell epithelial cells full-length half-life half-maximal effective concentration half-maximal inhibitory concentration help host cell human lung in vivo Influenza influenza viruses inhibiting inhibitor lead lung lung cell lung tissue mechanism MERS-CoV mice Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus nafamostat other coronavirus other coronaviruses Pathogenesis pharmacokinetics plasma probe protease Protease inhibitor PROTECT Protein PS-SCL respiratory respiratory syndrome coronavirus SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 virus selective Serine serine protease TMPRSS2 severe acute respiratory syndrome Coronavirus Significance significantly specificity Spike protein stability structure-based drug discovery the Spike therapeutic target TMPRSS2 TMPRSS2 inhibitor TMPRSS2 inhibitors TMPRSS2 protein treat Treatment Viral viral entry viral pathogenesis Viral protein viral spread virus [DOI] 10.1073/pnas.2108728118 PMC 바로가기 [Article Type] 410